Natixis Advisors LLC Purchases 121,530 Shares of Sanofi $SNY

Natixis Advisors LLC boosted its position in Sanofi (NASDAQ:SNY) by 3.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,234,911 shares of the company’s stock after buying an additional 121,530 shares during the period. Natixis Advisors LLC’s holdings in Sanofi were worth $156,764,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CSM Advisors LLC bought a new stake in Sanofi in the 3rd quarter valued at about $18,244,000. Caprock Group LLC bought a new stake in Sanofi in the 3rd quarter valued at about $1,347,000. Assetmark Inc. increased its position in Sanofi by 25.0% in the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after buying an additional 71,356 shares in the last quarter. XY Capital Ltd bought a new stake in Sanofi in the 3rd quarter valued at about $1,603,000. Finally, Regal Partners Ltd increased its position in Sanofi by 7.1% in the 3rd quarter. Regal Partners Ltd now owns 1,657,539 shares of the company’s stock valued at $78,236,000 after buying an additional 109,335 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

Sanofi Price Performance

Sanofi stock opened at $42.96 on Tuesday. Sanofi has a 12 month low of $42.33 and a 12 month high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The business’s 50 day simple moving average is $45.57 and its 200 day simple moving average is $46.96. The company has a market cap of $104.15 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 1.08 and a beta of 0.34.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a dividend of $2.4225 per share. The ex-dividend date of this dividend is Monday, May 4th. This represents a dividend yield of 559.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is currently 49.16%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.